Market Overview

Emergent Biosolutions Secures Exclusive US Commercial Rights to NextGen Pandemic Influenza Vaccine Candidate

Related EBS
4 Biotech Stocks To Better Your Financial Health This Winter
Why Is Emergent Biosolutions (EBS) Up 3.9% Since the Last Earnings Report?
Your Daily Pharma Scoop: Omeros Potential, Portola's Setback, Proteostasis Soars (Seeking Alpha)

Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has signed a license agreement with VaxInnate Corporation under which Emergent acquired the exclusive right to manufacture and sell VaxInnate's pandemic influenza vaccine candidate in the United States. The product candidate, a recombinant vaccine, has the potential to be produced quickly, at high yields and in a cost-effective manner. This license enables Emergent to fulfill the requirement to secure a pandemic influenza vaccine candidate under its contract with the Biomedical Advanced Research and Development Authority (BARDA), which established Emergent as a Center for Innovation in Advanced Development and Manufacturing (Center) in June 2012. VaxInnate will continue to develop its pandemic influenza vaccine candidate under its current BARDA contract and Emergent will manufacture the pandemic influenza vaccine candidate using flexible manufacturing technology.

Posted-In: News


Related Articles (EBS)

View Comments and Join the Discussion!

Partner Center